Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HIV Immune and Virological Responses Following the Administration of IL-2 Either Alone or Combined to ALVAC-HIV 1433 and HIV Lipopeptides in Patients Treated Early With HAART During Primary Infection

This study has been terminated.
Sponsor:
Collaborator:
Aventis Pharmaceuticals
Information provided by:
French National Agency for Research on AIDS and Viral Hepatitis
ClinicalTrials.gov Identifier:
NCT00196651
First received: September 12, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: February 2004
  Estimated Primary Completion Date: No date given
No publications provided by French National Agency for Research on AIDS and Viral Hepatitis

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):